156865-72-4

Upstream product

• 897046-42-3 1-[(1,1-dimethylethoxy)-carbonyl]-4-hydroxy-2-pyrrolidine carboxylic acid methyl ester 

Downstream Products

• 362706-25-0 tert-butyl 2-methyl-4-oxopyrrolidine-1-carboxylate 
• 1584148-14-0 N-((R)-1-(3-chlorophenyl)ethyl)-5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxamide 

Relevant academic research and scientific papers

DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERKl and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics

N-heterocyclic inhibitors of TNF-α expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

N-heterocyclic inhibitors of TNF-alpha expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

N- heterocyclic inhibitors of TNF-alpha expression

N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.